搜尋結果
BNT162b2疫苗是德國BioNTech與美國輝瑞製藥各投入一半開發經費的研發成果 [20] ，在開發初期更由輝瑞承擔全部研發經費 [21] ，BioNTech則在疫苗上市後向輝瑞分期還款 [22] ，BNT162b2疫苗於2020年12月成為首種研發成功並實用化的核糖核酸疫苗 [23] 。 美國食藥局已批准BNT162b2疫苗可供6個月或以上的嬰兒、兒童、青少年及成年人接種 [24] 。
The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with the American company Pfizer to carry out clinical trials , logistics, and manufacturing.
- Should Pregnant and Breastfeeding Women Be Vaccinated?
- Who Should Not Take The Vaccine?
- Is This Vaccine Recommended For Children and Adolescents?
- How Efficacious Is The Vaccine?
- What Is The Recommended Dosage?
- Is A Booster Dose Recommended For This Vaccine?
- Can This Vaccine Be ‘Mixed and Matched’ with Other Vaccines?
- Does It Prevent Infection and Transmission?
- Does It Work Against New Variants?
- How Does This Vaccine Compare to Other Covid-19 Vaccines in use?
Given the adverse consequences of COVID-19 disease during pregnancy and the increasing data supporting a favorable safety profile of BNT162b2 in pregnancy, WHO recommends the use of BNT162b2 in pregnant individuals. WHO does not recommend pregnancy testing prior to vaccination. WHO does not recommend delaying pregnancy or terminating pregnancy beca...
People with a history of severe allergic reaction to any component of the vaccine should not take it. Anyone with fever (body temperature over 38.5 ºC) should postpone vaccination until they are afebrile.
This vaccine is authorized for use for those aged 6 months and older, with an adjustment in the recommended dosage for those aged 6 months to 4 years, and an adjustment for those aged 5-11 years. WHO recommends that countries should consider using the vaccine in children aged 6 months and older to 17 only when high vaccine coverage with 2 doses has...
The Pfizer BioNTech vaccine against COVID-19 has very high efficacy against severe disease and moderate efficacy against symptomatic SARS-CoV-2 infection.
For all persons aged 12 years and above, SAGE recommends two doses (30 µg, 0.3 ml each), 4-8 weeks apart given intramuscularly into the deltoid muscle. For children aged 5 to 11 years SAGE recommends two doses (10 µg, 0.2 ml each) given intramuscularly into the deltoid muscle and provided 4-8 weeks apart, preferentially 8 weeks. For infants and chi...
The first booster dose is recommended for the highest priority-use groups (e.g. older adults, persons with moderate to severe immunocompromising conditions, and health workers) followed by lower priority-use groups, 4-6 months after the completion of the primary series. If more than 6 months have elapsed since completion of the primary series, the ...
SAGE accepts two doses from different COVID-19 vaccine platforms of WHO Emergency Use Listing (EUL) COVID-19 vaccines as a complete primary series. For countries considering mix-and match schedules, WHO has made recommendations to ensure equivalent or favourable immunogenicity or vaccine effectiveness for heterologous versus homologous schedules: 1...
There is modest vaccine impact on transmission. In the meantime, we must maintain and strengthen public health measures that work: masking, physical distancing, handwashing, respiratory and cough hygiene, avoiding crowds, and ensuring good ventilation.
The vaccine remains effective against virus variants, though for the Omicron variant, vaccine effectiveness against severe and mild disease after two doses is lower compared to Delta, and waning is more rapid. Therefore, a third dose (first booster) is recommended for all adults, and a second booster for the highest priority-use groups.
It is impossible to compare vaccines head-to-head due to the different approaches taken in designing the respective studies, but overall, all of the vaccines that have achieved WHO Emergency Use Listing are highly effective in preventing severe disease and hospitalization due to COVID-19. This webpage was updated on 18 August 2022 to reflect the la...
2021年12月6日 · BioNTech vaccine available at eight private healthcare institutions starting today (with photos) Members of the public, starting from today (December 6), can make appointments to receive the BioNTech vaccine at 24 vaccination venues of the eight private healthcare institutions that have enrolled in the BioNTech vaccination pilot scheme.
2022年4月1日 · 輝瑞/BioNTech疫苗是全球第一款獲世界衛生組織（WHO）批准緊急使用的新冠疫苗，2020年12月先後在英國和美國獲准群體接種。 關於輝瑞/BioNTech疫苗，下面是幾個你可能感興趣的問題。 初期數據顯示，輝瑞（Pfizer）和德國醫藥公司BioNTech研製成的新冠疫苗有效率高達90%。 效力多大？...
地點完全接種比例總劑數全球6112120524547中國大陸、香港和澳門873403643000印度661978918170美國675962334892022年8月18日 · Русский. Español. Português. 为体现免疫战略咨询专家组最新建议，于2022年8月18日更新。 世卫组织免疫战略咨询专家组已发布使用辉瑞-生物科技（BNT162b2）COVID-19疫苗的临时建议。 本文对这些临时建议做了归纳。 你可以在 此处 查阅完整指导文件。 以下是你需要了解的内容。 免疫战略咨询专家组认为，辉瑞-生物科技COVID-19 mRNA疫苗安全有效。 哪些人可以接种该疫苗？ 该疫苗对6个月龄及以上的所有个人都安全有效。 根据 世卫组织优先次序路线图 和 世卫组织价值观框架 ，老年人、免疫功能低下者和卫生工作者为最高优先使用群体。 应尽一切努力在最高和高度优先使用群体中实现高疫苗接种覆盖率。 孕妇和哺乳期妇女是否应接种疫苗？
2023年9月11日 · The Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) is authorized for all doses administered to individuals 6 months through 11 years of age to prevent COVID-19. The...
